Education
About Us
Working with TipRanks
Follow Us
Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
AVR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.94 - $8.79
Previous Close$5.88
Volume157.53K
Average Volume (3M)248.14K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)4.07M
Price to Earnings (P/E)―
Beta1.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding36,023,796
10 Day Avg. Volume489,697
30 Day Avg. Volume248,142
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.50Price Target Upside118.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Anteris Technologies Global Corp. News
PremiumCompany Announcements
Anteris Technologies Achieves Key Milestone in Cardiac Care
PremiumCompany Announcements
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe DurAVR system has shown premier acute and long-term hemodynamic outcomes in first-in-human and early feasibility studies, signaling potential success in upcoming pivotal studies.
Clinical OutcomesPreliminary cardiac MR data from DurAVR patients have shown less LV strain, significant LV mass regression, and a reduction of the LV mass index, indicating favorable reverse remodeling.
Innovative TechnologyAnteris has created a single-piece, native-shaped biomimetic valve design built to mimic the performance of a native healthy aortic valve, addressing unmet needs in the TAVR industry.
Regulatory ProgressAnteris released its Q4 results, highlighting significant progress toward securing FDA approval for the DurAVR TAVR system.
Bears Say
Market CompetitionAnteris has developed DurAVR, a first-in-class biomimetic TAVR platform with disruptive potential in the ~$10B TAVR market.
---
Ownership Overview
0.12% Insiders
38.95% Other Institutional Investors
60.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.94 and its highest was $8.79 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Currently, no data Available
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Currently, no data Available
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 36,023,796 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
---
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Our lead product, the DurAVR® transcatheter heart valve ("THV") system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and depoloyed with our ComASUR® balloon-expahndable delivery system. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
---
AVR Stock 12 Month Forecast
Average Price Target
$16.50
▲(118.25% Upside)
Technical Analysis
Best Analysts Covering AVR
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-47.80%
reiterated a buy rating 6 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.80% per trade.
---